It has been about a month since the last earnings report for Vertex Pharmaceuticals (VRTX). Shares have added about 2.7% in that time frame, outperforming the S&P 500. But investors have to be ...

If you have ever wondered whether Vertex Pharmaceuticals is a bargain right now, you are not alone. Let's break down whether the current price really stacks up to the company's fundamentals. Despite ...

A parabola, a fundamental shape in mathematics and physics, isn't just a curve we see in graphs; it’s a geometric entity defined by a very specific rule. Understanding the locus definition unlocks a ...

A parabola is a symmetrical, U-shaped curve. It's formally defined as the set of all points equidistant to a fixed point (the focus) and a fixed line (the directrix). Parabolas appear in various ...

Vertex, Inc. shares have plunged over 60% YTD, but valuation is now compelling after a post-earnings dip. VERX offers steady low-teens growth, expanding margins, and a sticky tax compliance software ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit a snag on its path to expand the potential blockbuster’s reach into ...

Boston and London biotech company Vertex Pharmaceuticals is on a roll. In the past year and a half, Vertex worked with CRISPR Therapeutics to develop the first CRISPR treatment approved by the U.S.

Vertex Rail Technologies opened in Wilmington in 2014 with promises of over 1,300 jobs and a $60 million investment. Despite initial optimism and orders, the company faced setbacks including federal ...

Vertex Pharmaceuticals is pressing pause on a phase 1/2 cystic fibrosis (CF) trial over a tolerability issue while reporting a separate impairment charge of $379 million tied to an earlier ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX). Compared to the S&P 500 index, which is down about 16% ...